
Opinion|Videos|June 17, 2024
Quality of Life and Progression Considerations in BCG-Unresponsive NMIBC
Bladder cancer experts discuss quality of life and progression considerations and their impact on treatment decisions for patients with BCG-unresponsive NMIBC.
Advertisement
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves first-line Zenflow system for the treatment of BPH
2
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
EMA recommends conditional approval of Anktiva in BCG-unresponsive NMIBC
5



















